Skip to main content
. Author manuscript; available in PMC: 2024 Feb 1.
Published in final edited form as: Mol Carcinog. 2022 Oct 26;62(2):236–248. doi: 10.1002/mc.23479

Fig. 2. CD44v6 maintains the cancer phenotype and YAP1 levels.

Fig. 2

A/B/C Targeted CD44v6-siRNA treatment reduces SCC-13 cell spheroid formation, invasion, and migration. D Immunoblot confirms CD44v6 knockdown and associated reduction in YAP1 and YAP1-P. E/F/G CD44v6-siRNA treatment reduces HaCaT cell spheroid formation, invasion, and migration. H CD44v6 knockdown HaCaT cells display reduced YAP1 and YAP1-P levels. I Control- and CD44v6-siRNA treated cells were transfected with EV-Luc or 8xTllC-luc vector. CD44v6 knockdown reduces YAP1/TEAD transcriptional activity in both cell types. J CD44v6-siRNA treatment reduces the mRNA abundance of the YAP1 target genes, CYR61 and CCND1. The single asterisk indicates a significant decrease, n = 3, p < 0.001.